NasdaqGS:INDVPharmaceuticals
The Bull Case For Indivior (INDV) Could Change Following New SUBLOCADE Fentanyl-User Efficacy Data
Indivior PLC recently reported positive randomized, double-blind clinical trial results showing that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® reduced opioid use and supported abstinence in people with moderate-to-severe opioid use disorder, without new safety signals.
A key insight from the post-hoc analyses was that the 300-mg monthly dose outperformed the 100-mg dose in participants with high-frequency fentanyl use, underlining SUBLOCADE®’s potential relevance for...